How should we treat AL amyloidosis in 2019?

The Multiple Myeloma Hub were pleased to speak to Suzanne Lentzsch, Columbia University, New York, US, about the treatment of AL amyloidosis in 2019. She highlights the importance of correct diagnosis and recommends its confirmation by mass spectrometry. Although CyBorD remains the standard of care, the addition of daratumumab might enhance the response. She states that allo-HSCT is still a popular choice especially in patients with early-stage disease and gives an overview of the clinical developments in the treatment of relapsed multiple myeloma, such as promising results from venetoclax studies.